---
title: "CINGULATE INC C/WTS 10/12/2026 (TO PUR COM) | 8-K: FY2026 Q1 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286414457.md"
datetime: "2026-05-14T12:12:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286414457.md)
  - [en](https://longbridge.com/en/news/286414457.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286414457.md)
generator: "portal-rs"
---

# CINGULATE INC C/WTS 10/12/2026 (TO PUR COM) | 8-K: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

### Financial Performance for the Three Months Ended March 31, 2026

#### Cash and Working Capital

-   **Cash and cash equivalents**: Cingulate Inc. reported $25,893,210 as of March 31, 2026, an increase from $10,953,383 as of December 31, 2025, primarily due to $14.9 million raised in the first quarter, including a $12.0 million private placement .
-   **Working Capital**: The company’s working capital increased to $16,952,085 as of March 31, 2026, compared to $1,695,633 as of December 31, 2025 .

#### Operating Expenses

-   **Research and Development (R&D) Expenses**: R&D expenses were $2,184,318 for the three months ended March 31, 2026, marking a 1.8% decrease from $2,222,626 for the same period in 2025 . This decrease was attributed to lower clinical operations costs, partially offset by increased regulatory and manufacturing activities for the CTx-1301 NDA review .
-   **General and Administrative (G&A) Expenses**: G&A expenses rose to $5,738,904 for the three months ended March 31, 2026, up from $1,483,409 for the same period in 2025, mainly due to costs associated with building out commercial infrastructure for CTx-1301 .

#### Profitability

-   **Operating Loss**: The operating loss for the three months ended March 31, 2026, was -$7,923,222, compared to -$3,706,035 for the same period in 2025 .
-   **Net Loss**: Cingulate Inc. reported a net loss of -$9,312,089 for the three months ended March 31, 2026, an increase from -$3,852,678 for the three months ended March 31, 2025 . This higher net loss resulted from increased G&A expenses and changes in the fair value of derivatives and interest on notes payable .
-   **Change in fair value of derivative**: The change in fair value of derivative was -$852,030 for Q1 2026, compared to -$49,987 for Q1 2025 .
-   **Interest and other income (expense), net**: This figure was -$536,837 for Q1 2026, compared to -$96,656 for Q1 2025 .
-   **Loss before income taxes**: The loss before income taxes was -$9,312,089 for Q1 2026, compared to -$3,852,678 for Q1 2025 .

#### Balance Sheet Highlights (as of March 31, 2026)

-   **Total assets**: Total assets stood at $30,861,701 .
-   **Total liabilities**: Total liabilities were $11,996,835 .
-   **Accumulated deficit**: The accumulated deficit was -$141,687,120 .
-   **Total stockholders’ equity**: Total stockholders’ equity was $18,864,866 .

### Outlook and Guidance

Cingulate Inc. anticipates its current resources will provide an extended cash runway into 2027, funding operations and supporting key milestones for CTx-1301 . The company is actively engaging with the FDA regarding its CTx-1301 New Drug Application (NDA), which has a PDUFA target action date of May 31, 2026 . Cingulate Inc. is also advancing commercialization preparations to enable a rapid launch contingent upon FDA approval .

### Related Stocks

- [CINGW.US](https://longbridge.com/en/quote/CINGW.US.md)

## Related News & Research

- [TriMas (TRS) Could Be 12% Undervalued Following Raised Earnings Guidance](https://longbridge.com/en/news/296887641.md)
- [Ktesios Real Estate Socimi signs EUR 12 million 15-year mortgage loan with Deutsche Bank](https://longbridge.com/en/news/296892100.md)
- [Diamondback Energy declares Q3 2026 dividend of R$ 0.24 per unit, payable Aug. 26](https://longbridge.com/en/news/296786776.md)
- [Rocket Lab Just Won a $12 Million Contract. The Real Prize Could Be Much Bigger.](https://longbridge.com/en/news/296390985.md)
- [Callan JMB to buy Reger Oil Williston Basin assets for $12 million mix of preferred stock and cash](https://longbridge.com/en/news/296770413.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**